BD (Becton, Dickinson and Company) has announced plans to spin off its Diabetes Care business as an independent, publicly traded company – NewCo as part of the company’s 2025 strategy. “The spinoff will allow BD to strengthen its growth profile, enables a greater investment focus on our other core businesses and high-growth opportunities, and makes a greater impact for our customers and patients,” says Tom Polen, chairman, CEO and president of BD. “We are proud of BD’s leadership in driving innovation to support people with diabetes and believe this transaction will empower NewCo to advance a more focused strategy and capital allocation policy to further advance innovation and growth specific to its unique market. As a standalone public company, we believe NewCo will be better positioned to leverage its leadership position in insulin delivery to advance vital, innovative solutions to the large and growing number of people living with diabetes worldwide. We believe today’s announcement demonstrates our commitment to maximize long-term value for all stakeholders — including our patients, customers, employees and shareholders.”
To read more, CLICK HERE.
